Teva Pharmaceutical Industries Limited's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shows the company is paying down debt, which reduces future interest payments and financial obligations.
Quarterly earnings reports show investors how much money the company made or lost and if business is improving.
Board members make important decisions about the company's direction and strategy.
Quarterly earnings reports show investors how much money the company made or lost and if business is improving.
Buying another company can help a pharmaceutical firm add new medicines and grow its business.
Annual earnings reports show how profitable the company was over the entire year.
Year-end earnings reports show total annual profit or loss and help investors evaluate yearly performance.
Stocky reads Teva Pharmaceutical Industries Limited's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Teva Pharmaceutical Industries Limited's most recent tracked filing was a 10-Q on 29 Jul 2026: Repaid $23 million convertible debentures in February.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.